Corbus Pharmaceuticals Holdings, Inc. (CRBP) Announces Presentation of Six Abstracts and New Anabasum Data

0
387

Corbus Pharmaceuticals Announces Presentation of Six Abstracts and New Anabasum Data at 2017 ACR Annual Meeting

Summarized below are the abstract titles that have been selected for oral or poster presentations. The ACR abstracts are available online at the conference website. Information from the ACR presentations are under embargo until November 4, 2017 at 4:30 PM PDT. Once the posters are made public, they will be available on the Company’s website in the Presentations section.

Sunday, November 5, 2017

Session: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Clinical Aspects and Therapeutics Poster I
Time: 9:00 – 11:00 AM PDT
Presenter: Robert Spiera, M.D., Director of the Vasculitis and Scleroderma Program at the Hospital for Special Surgery, Weill Cornell Medical College in New York City and Principal Investigator of the Phase 2 study in systemic sclerosis
Abstract #725: Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in An Open-Label Extension of Trial JBT101-SSc-001

Session: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Clinical Aspects and Therapeutics Poster I
Time: 9:00 – 11:00 AM PDT
Presenter: Barbara White, M.D., Chief Medical Officer of Corbus
Abstract #738: Prospective Validation of the Scleroderma Skin Patient-reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Session: Innate Immunity and Rheumatic Disease Poster I
Time: 9:00 – 11:00 AM PDT
Presenter: Mark A. Tepper, Ph.D., Chief Scientific Officer of Corbus
Abstract #298: Anabasum (JBT-101) Enhances Resolution of Inflammation in Humans

Monday, November 6, 2017

Session: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics Poster II
Time: 9:00 – 11:00 AM PDT
Presenter: Viktor Martyanov, Ph.D., Research Scientist at the Geisel School of Medicine at Dartmouth, Department of Molecular and Systems Biology
Abstract #1707: Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial

Tuesday, November 7, 2017

Session: Muscle Biology, Myositis and Myopathies Poster
Time: 9:00 – 11:00 AM PDT
Presenter: Victoria Werth, M.D., Professor of Dermatology and Medicine at the University of Pennsylvania School of Medicine and Principal Investigator of Corbus’ Phase 2 study in Dermatomyositis
Abstract #2156: Comparison of Patients with Dermatomyositis in a Specialty Clinic Versus Clinical Trial with Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist

Session: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Clinical Aspects and Therapeutics II
Time: 4:30 – 6:00 PM PDT
Presenter: Robert Spiera, M.D., Director of the Vasculitis and Scleroderma Program at the Hospital for Special Surgery, Weill Cornell Medical College in New York City and Principal Investigator of the Phase 2 study in systemic sclerosis
Abstract #2884: A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist in Diffuse Cutaneous Systemic Sclerosis

About Anabasum

Anabasum is a synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Preclinical and human clinical studies have shown anabasum to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in preclinical models of inflammation and fibrosis. Anabasum is designed to trigger the production of “Specialized Pro-resolving Lipid Mediators” that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of multiple inflammatory mediators. Anabasum also is designed to have a direct effect on fibroblasts to halt tissue scarring. In effect, anabasum is believed to trigger endogenous pathways to turn “off” chronic inflammation and fibrotic processes, without causing immunosuppression.

LEAVE A REPLY

Please enter your comment!
Please enter your name here